155 related articles for article (PubMed ID: 22961302)
1. Cyclic strain amplitude dictates the growth response of vascular smooth muscle cells in vitro: role in in-stent restenosis and inhibition with a sirolimus drug-eluting stent.
Colombo A; Guha S; Mackle JN; Cahill PA; Lally C
Biomech Model Mechanobiol; 2013 Aug; 12(4):671-83. PubMed ID: 22961302
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model.
Yang W; Ge J; Liu H; Zhao K; Liu X; Qu X; Li W; Huang Y; Sun A; Zou Y
Cardiovasc Res; 2006 Dec; 72(3):483-93. PubMed ID: 17020754
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells.
Clever YP; Cremers B; Krauss B; Böhm M; Speck U; Laufs U; Scheller B
EuroIntervention; 2011 May; 7 Suppl K():K32-42. PubMed ID: 22027725
[TBL] [Abstract][Full Text] [Related]
4. Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents.
Chieffo A; Foglieni C; Nodari RL; Briguori C; Sangiorgi G; Latib A; Montorfano M; Airoldi F; Michev I; Carlino M; Colombo A; Maseri A
Am J Cardiol; 2009 Dec; 104(12):1660-7. PubMed ID: 19962471
[TBL] [Abstract][Full Text] [Related]
5. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery.
Wessely R; Blaich B; Belaiba RS; Merl S; Görlach A; Kastrati A; Schömig A
Thromb Haemost; 2007 Jun; 97(6):1003-12. PubMed ID: 17549304
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53.
Rosner D; McCarthy N; Bennett M
Cardiovasc Res; 2005 Jun; 66(3):601-10. PubMed ID: 15914125
[TBL] [Abstract][Full Text] [Related]
7. Two-dimensional fluorescence in-gel electrophoresis of coronary restenosis tissues in minipigs: increased adipocyte fatty acid binding protein induces reactive oxygen species-mediated growth and migration in smooth muscle cells.
Lu L; Wang YN; Sun WH; Liu ZH; Zhang Q; Pu LJ; Yang K; Wang LJ; Zhu ZB; Meng H; Yang P; Du R; Chen QJ; Wang LS; Yu H; Shen WF
Arterioscler Thromb Vasc Biol; 2013 Mar; 33(3):572-80. PubMed ID: 23372061
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of different outcomes for drug-eluting stents that release sirolimus or tacrolimus.
Giordano A
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):159-68. PubMed ID: 20205050
[TBL] [Abstract][Full Text] [Related]
9. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells.
Matter CM; Rozenberg I; Jaschko A; Greutert H; Kurz DJ; Wnendt S; Kuttler B; Joch H; Grünenfelder J; Zünd G; Tanner FC; Lüscher TF
J Cardiovasc Pharmacol; 2006 Dec; 48(6):286-92. PubMed ID: 17204907
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy.
Curcio A; Torella D; Indolfi C
Circ J; 2011; 75(6):1287-96. PubMed ID: 21532177
[TBL] [Abstract][Full Text] [Related]
11. Effect of a novel peptide, WKYMVm- and sirolimus-coated stent on re-endothelialization and anti-restenosis.
Jang EJ; Bae IH; Park DS; Lee SY; Lim KS; Park JK; Shim JW; Sim DS; Jeong MH
J Mater Sci Mater Med; 2015 Oct; 26(10):251. PubMed ID: 26438653
[TBL] [Abstract][Full Text] [Related]
12. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
[TBL] [Abstract][Full Text] [Related]
13. Comparison of long-term results of drug-eluting stent and bare metal stent implantation in heart transplant recipients with coronary artery disease.
Zakliczynski M; Lekston A; Osuch M; Swierad M; Nadziakiewicz P; Przybylski R; Zembala M
Transplant Proc; 2007 Nov; 39(9):2859-61. PubMed ID: 18022002
[TBL] [Abstract][Full Text] [Related]
14. Influence of Clinically Relevant Mechanical Forces on Vascular Smooth Muscle Cells Under Chronic High Glucose: An In Vitro Dynamic Disease Model.
Chawla V; Simionescu A; Langan EM; LaBerge M
Ann Vasc Surg; 2016 Jul; 34():212-26. PubMed ID: 27126714
[TBL] [Abstract][Full Text] [Related]
15. A perlecan-inducing compound significantly inhibits smooth muscle cell function and in-stent intimal hyperplasia: novel insights into the diverse biological effects of perlecan.
Segev A; Nili N; Osherov AB; Qiang B; Wong AJ; Pillarisetti S; Strauss BH
EuroIntervention; 2010 May; 6(1):134-40. PubMed ID: 20542809
[TBL] [Abstract][Full Text] [Related]
16. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
[TBL] [Abstract][Full Text] [Related]
17. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model.
Tada N; Virmani R; Grant G; Bartlett L; Black A; Clavijo C; Christians U; Betts R; Savage D; Su SH; Shulze J; Kar S
Circ Cardiovasc Interv; 2010 Apr; 3(2):174-83. PubMed ID: 20407114
[TBL] [Abstract][Full Text] [Related]
18. Drug-eluting stents.
García-García HM; Vaina S; Tsuchida K; Serruys PW
Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
[TBL] [Abstract][Full Text] [Related]
19. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
[TBL] [Abstract][Full Text] [Related]
20. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
